Regeneron Pharmaceuticals/ US75886F1075 /
| 20.12.2024 21:59:50 | Diff. - | Volumen | Geld22:25:01 | Brief22:25:01 | Marktkapitalisierung | Dividendenr. | KGV |
|---|---|---|---|---|---|---|---|
| 702,03USD | - | 21.325 Umsatz: 5,06 Mio. |
-Geld Vol: - | -Brief Vol: - | 77,13 Mrd.USD | - | 18,94 |
Aktiva
|
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
2022 US GAAP in Mio. USD |
2023 US GAAP in Mio. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sachanlagen | 2.890,4000 | 3.221,6000 | 3.482,2000 | 3.763 | 4.146,4000 | ||||||
| Immaterielle Vermögensgegenstände | - | - | - | 915,5000 | 1.038,6000 | ||||||
| Finanzanlagen | 3.256,8000 | 3.135,6000 | 6.838 | 6.591,8000 | 5.396,5000 | ||||||
| Anlagevermögen | 7.116,1000 | 7.384,2000 | 11.419,9000 | 13.330,4000 | 13.601 | ||||||
| Vorräte | 1.415,5000 | 1.916,6000 | 1.951,3000 | 2.401,9000 | 2.580,5000 | ||||||
| Forderungen | 2.100 | 3.111,5000 | 6.036,5000 | 5.328,7000 | 5.667,3000 | ||||||
| Liquide Mitteln | 1.617,8000 | 2.193,7000 | 2.885,6000 | 3.105,9000 | 2.730 | ||||||
| Umlaufvermögen | 7.689,1000 | 9.779,1000 | 14.014,9000 | 15.884,1000 | 19.479,2000 | ||||||
| Aktiva, gesamt | 14.805,2000 | 17.163,3000 | 25.434,8000 | 29.214,5000 | 33.080,2000 | ||||||
Passiva
|
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
2022 US GAAP in Mio. USD |
2023 US GAAP in Mio. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Verbindlichkeiten aus Lieferungen und Leistungen | 418,1000 | 475,5000 | 564 | 589,2000 | 606,6000 | ||||||
| Langfristige Schulden | 713,9000 | 2.695,7000 | 1.980 | 2.701,4000 | 2.702,9000 | ||||||
| Verbindlichkeiten gegenüber Kreditinstituten | - | - | - | - | - | ||||||
| Rückstellungen | - | - | - | - | - | ||||||
| Verbindlichkeiten | 3.715,5000 | 6.138 | 6.666 | 6.550,5000 | 7.107,1000 | ||||||
| Gezeichnetes Kapital | ,1000 | ,1000 | ,1000 | ,1000 | ,1000 | ||||||
| Eigenkapital | 11.089,7000 | 11.025,3000 | 18.768,8000 | 22.664 | 25.973,1000 | ||||||
| Minderheitenanteile | - | - | - | - | - | ||||||
| Passiva, gesamt | 14.805,2000 | 17.163,3000 | 25.434,8000 | 29.214,5000 | 33.080,2000 | ||||||
Gewinn- und Verlustrechnung
|
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
2022 US GAAP in Mio. USD |
2023 US GAAP in Mio. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 7.863,4000 | 8.497,1000 | 16.071,7000 | 12.172,9000 | 13.117,2000 | ||||||
| Abschreibungen (Gesamt) | - | - | - | - | - | ||||||
| Betriebsergebnis | 2.209,8000 | 3.576,6000 | 8.946,8000 | 4.738,9000 | 4.047,1000 | ||||||
| Zinsergebnis | -30,2000 | -56,9000 | -57,3000 | -59,4000 | -73 | ||||||
| Ergebnis vor Steuern | 2.429,1000 | 3.810,4000 | 9.325,8000 | 4.858,8000 | 4.199,3000 | ||||||
| Ertragsteuern | -313,3000 | 297,2000 | 1.250,5000 | 520,4000 | 245,7000 | ||||||
| Gewinnanteil Minderheitsgesellschafter | - | - | - | - | - | ||||||
| Konzernjahresüberschuss | 2.115,8000 | 3.513,2000 | 8.075,3000 | 4.338,4000 | 3.953,6000 | ||||||
Pro Aktie
Cash Flow
|
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
2021 US GAAP in Mio. USD |
2022 US GAAP in Mio. USD |
2023 US GAAP in Mio. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow aus laufender Geschäftstätigkeit | 2.430 | 2.618,1000 | 7.081,3000 | 5.014,9000 | 4.594 | ||||||
| Cash Flow aus Investitionstätigkeit | -2.027,8000 | -70,6000 | -5.384,7000 | -3.784,6000 | -3.185,1000 | ||||||
| Cash Flow aus Finanzierungstätigkeit | -252,1000 | -1.970,5000 | -1.005,8000 | -1.009 | -1.790,1000 | ||||||
| Veränderung der liquiden Mittel | 150,1000 | 577 | 690,8000 | 221,3000 | -381,6000 | ||||||
| Anzahl der Mitarbeiter | 8.100 | 9.123 | 10.368 | - | - | ||||||
